Fig. 5From: Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cellsAlteration of chemokine receptor expression on circulatory osteoclast progenitors (OCPs) in follow-up of anti-TNF therapy. a Proportion of OCPs (CD3−CD19−CD56−CD11b+CD14+) and their subsets expressing macrophage colony-stimulating factor receptor (CD115) and receptor activator of nuclear factor-κB (RANK) in peripheral blood of patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) before (0) and 2, 4, and 6 months after induction of anti-TNF therapy (etanercept 50 mg weekly or adalimumab 40 mg every 2 weeks). b Subsets of OCPs expressing chemokine receptors with regard to duration of anti-TNF therapy in patients with RA and patients with PsA. Values are presented as median with IQR for each time point. Analysis for linear trend was performed using one-way analysis of variance with polynomial contrast type. p Values <0.05 are shown. CCR CC chemokine receptor, CXCR CXC chemokine receptorBack to article page